Ascend Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ascend Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-110,663	Closed	-$19.1M	–	199
2018 Q2	$19.1M	Buy	+110,663	New	+$18.1M	0.9%	40
2016 Q2	–	Sell	-15,000	Closed	-$1.96M	–	157
2016 Q1	$1.96M	Buy	+15,000	New	+$1.87M	0.19%	85
2015 Q3	–	Sell	-92,567	Closed	-$16.3M	–	145
2015 Q2	$16.3M	Buy	+92,567	New	+$16.6M	0.54%	68

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Ascend Capital's JAZZ Position: Q3 2018 in Review

Ascend Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2018, closing a stake of 110,663 shares — an estimated $19.1M sold.

Ascend Capital first reported a position in JAZZ in Q2 2015 and held it in 3 quarters. The position peaked at $19.1M in Q2 2018. 403 funds tracked by Wall St. Rank hold JAZZ as of Q3 2018.

Ascend Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Ascend Capital sold 110,663 Jazz Pharmaceuticals shares in Q3 2018, an estimated $19.1M.
Ascend Capital first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Ascend Capital's Jazz Pharmaceuticals position peaked at $19.1M in Q2 2018.
403 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.